NEW YORK (GenomeWeb News) – Cancer diagnostics services firm BioTheranostics today announced a contract with preferred provider organization Three Rivers Provider Network.

The contract covers the San Diego firm's testing services, including CancerType ID for diagnosing metastatic cancer, and Breast Cancer Index for predicting the risks of recurrence of early stage, estrogen receptor-positive breast cancer. The agreement makes BioTheranostics' tests available to an additional 15 million covered lives in the US, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.